版本:
中国

BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study

April 20 Atossa Genetics Inc:

* Atossa Genetics receives positive interim review from independent safety committee in phase 1 Endoxifen dose escalation study

* Atossa Genetics- independent safety committee reviewed blinded data from first cohort of study, concluded that study may advance to next dosing level Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐